I-MAB (IMAB) Price & Analysis

Compare

368 Followers

IMAB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.60 - $4.10

Previous CloseN/A

Volume876.01K

Average Volume (3M)2.24M

Market Cap

$266.03M

Enterprise Value-$102.69M

Total Cash (Recent Filing)$184.39M

Total Debt (Recent Filing)$3.78M

Price to Earnings (P/E)―

Beta1.77

Next Earnings

Sep 02, 2025

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding81,660,350

10 Day Avg. Volume5,671,749

30 Day Avg. Volume2,236,300

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.39

Enterprise Value/Revenue-25.71

Enterprise Value/Gross Profit-25.71

Enterprise Value/Ebitda0.34

Forecast

1Y Price Target

$5.67

Price Target Upside61.54% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyClinical data for Givastomig shows an 83% overall response rate, which is favorable compared to the approximately 40% response rate of a competitor's treatment.

Patient CoverageGivastomig offers industry-leading Claudin 18.2 patient coverage, enabled by a uniquely permissive ≥1% expression threshold, compared to zolbetuximab's ≥75% cutoff.

Safety ProfileGivastomig continues to demonstrate a differentiated and manageable safety profile, with no dose-limiting toxicities or grade 4/5 TRAEs, and only isolated grade 3 events.

Bears Say

Potential CompetitionAs the data matures, it will be important for giva to demonstrate a mPFS at least as long as the one seen for zolbi + chemo.

Side EffectsGrade ≥3 neutropenia was attributed to chemo and likely driven by a temporary restriction on the use of growth factors.

I-MAB News

3 Penny Stocks to Watch Now, 8/5/25

Tenon Medical, BioXcel Therapeutics, and I-Mab are the 3 Penny Stocks to watch on August 5, 2025, based on TipRanks’ Penny...

3d ago

BTAI

IMAB

Everest Medicines announces strategic equity investment in I-Mab

Everest Medicines announced that it has made a strategic equity investment in I-Mab (IMAB). Rogers Yongqing Luo, CEO...

7d ago

IMAB

I-Mab prices 33.3M ADSs at $1.95 in underwritten offering

I-Mab (IMAB) announced the pricing of an underwritten offering in the United States of 33,333,334 American Depositary Shares...

7d ago

IMAB

I-Mab entered into agreement to acquire 100% ownership of Bridge Health Biotech

I-Mab (IMAB) announced that it entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech....

22d ago

IMAB

I-Mab Announces $65 Million ADS Offering to Advance Cancer Treatment Pipeline

I-MAB ( ($IMAB) ) has issued an announcement. On August 1, 2025, I-Mab announced the pricing of an...

4d ago

IMAB

I-MAB Announces Preliminary Financial Results for Mid-2025

The latest update is out from I-MAB ( ($IMAB) ). On August 1, 2025, I-MAB announced its expected...

7d ago

IMAB

I-Mab Acquires Bridge Health to Boost Givastomig Portfolio

I-MAB ( ($IMAB) ) has shared an update. On July 17, 2025, I-Mab announced the acquisition of Bridge...

22d ago

IMAB

I-MAB Amends Prospectus for $21 Million ADS Offering

I-MAB ( ($IMAB) ) has provided an announcement. On July 11, 2025, I-MAB announced an amendment to its...

28d ago

IMAB

I-MAB’s Givastomig Shows Promising Efficacy and Safety in Gastric Cancer, Earning Buy Rating

H.C. Wainwright analyst Andres Y. Maldonado has maintained their bullish stance on IMAB stock, giving a Buy rating...

1M ago

IMAB

Promising Clinical Developments and Strong Performance Drive Buy Rating for I-MAB

Gil Blum, an analyst from Needham, maintained the Buy rating on I-MAB. The associated price target remains the...

1M ago

IMAB

I-Mab Reports Promising Phase 1b Results for Givastomig in Gastric Cancer

I-MAB ( ($IMAB) ) just unveiled an update. On July 2, 2025, I-Mab announced positive results from a...

1M ago

IMAB

I-Mab presents Gibastomig Phase 1b dose escalation data

I-Mab (IMAB) announced the presentation of Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6,...

1M ago

IMAB

I-Mab publishes givastomig monotherapy data in Clinical Cancer Research

I-Mab (IMAB) announced publication of the first-in-human monotherapy data for givastomig, a bispecific Claudin 18.2 x 4-1BB antibody,...

1M ago

IMAB

Promising Clinical Data and Rapid Enrollment Propel I-MAB’s Givastomig to a Buy Rating

Gil Blum, an analyst from Needham, maintained the Buy rating on I-MAB (IMAB – Research Report). The associated...

1M ago

IMAB

IMAB FAQ

What was I-MAB’s price range in the past 12 months?

I-MAB lowest stock price was $0.59 and its highest was $4.10 in the past 12 months.

What is I-MAB’s market cap?

I-MAB’s market cap is $266.03M.

When is I-MAB’s upcoming earnings report date?

I-MAB’s upcoming earnings report date is Sep 02, 2025 which is in 25 days.

How were I-MAB’s earnings last quarter?

Currently, no data Available

Is I-MAB overvalued?

According to Wall Street analysts I-MAB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does I-MAB pay dividends?

I-MAB does not currently pay dividends.

What is I-MAB’s EPS estimate?

I-MAB’s EPS estimate is -0.05.

How many shares outstanding does I-MAB have?

I-MAB has 81,660,350 shares outstanding.

What happened to I-MAB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of I-MAB?

Currently, no hedge funds are holding shares in IMAB

I-MAB Stock Smart Score

Outperform

Fundamentals

Return on Equity

-22.38%

Trailing 12-Months

Asset Growth

-42.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

I-MAB

I-MAB (IMAB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The company is engaged in the development of innovative monoclonal antibodies and biologics, leveraging its integrated research and development capabilities. I-MAB aims to address unmet medical needs through its proprietary drug discovery and development platforms.

I-MAB (IMAB) Earnings & Revenues

Historic Earnings Reports

IMAB Stock 12 Month Forecast

Average Price Target

$5.67

▲(61.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.34,2.6984615384615385,3.056923076923077,3.4153846153846152,3.773846153846154,4.132307692307693,4.490769230769231,4.849230769230769,5.207692307692308,5.5661538461538465,5.924615384615385,6.283076923076923,6.641538461538461,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.34,2.596153846153846,2.852307692307692,3.1084615384615386,3.3646153846153846,3.6207692307692305,3.876923076923077,4.133076923076923,4.389230769230769,4.645384615384615,4.901538461538461,5.157692307692308,5.413846153846154,{"y":5.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.34,2.5446153846153843,2.749230769230769,2.9538461538461536,3.1584615384615384,3.363076923076923,3.5676923076923073,3.772307692307692,3.976923076923077,4.181538461538461,4.386153846153846,4.590769230769231,4.795384615384615,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.94,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >